On one hand, since Charles Huggins initially observed the impact of androgen deprivation therapy (ADT) on metastatic PC patients, inhibition of androgen receptor signaling with ADT has been the basis of therapy for metastatic PC. The gene discussed is AR; the disease is pachyonychia congenita.